Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556059 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL10335706 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL7339574 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL4309898 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL11108585 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL4299442 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL15522266 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL2670678 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL2553275 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL4295210 | 0.98 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-10065950-B2 | Substituted thiazoles as HIV integrase inhibitors | JAPAN TOBACCO INC. (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-2940019-B1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20160046641-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2940019-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2540720-B1 | 1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE DERIVATIVE AND USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| WO-2005082459-A2 | METHOD OF DECREASING BLOOD CELLS | JAPAN TOBACCO INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | JAPAN TOBACCO INC. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-0849256-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375465-A9 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375479-A1 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | CCR1, CCL2, CCR5 | DNM1 3225/4885ZDHHC7 237/4885LCK 1176/4885 |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | IMPA1, IMPDH1, TYMP | DNM1 1102/4885ZDHHC7 2571/4885LCK 368/4885 |
| US-10065950-B2 | Substituted thiazoles as HIV integrase inhibitors | TYMP, TYMS, IMPDH1 | DNM1 1493/4885ZDHHC7 2371/4885LCK 183/4885 |
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | IMPDH1, IMPDH2, SAV1 | DNM1 2593/4885ZDHHC7 4127/4885LCK 894/4885 |
| US-20160046641-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | DNM1 2859/4885ZDHHC7 4292/4885LCK 742/4885 |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | TNF, IL1B, TNNI3 | DNM1 1766/4885ZDHHC7 564/4885LCK 1376/4885 |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | DNM1 2607/4885ZDHHC7 4210/4885LCK 676/4885 |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, SAV1 | DNM1 2593/4885ZDHHC7 4127/4885LCK 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.